The Journal of Nutritional Biochemistry
Volume 19, Issue 7 , Pages 417-437 , July 2008

Modulation of enzymatic activities by n-3 polyunsaturated fatty acids to support cardiovascular health

  • Rafat A. Siddiqui

      Affiliations

    • Cellular Biochemistry Laboratory, Methodist Research Institute, Clarian Health, Indianapolis, IN 46202, USA
    • Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    • Corresponding Author InformationCorresponding author. Cellular Biochemistry Laboratory, Methodist Research Institute, Clarian Health Partners, Indianapolis, IN 46202, USA. Tel.: +1 317 962 6941.
    • ,
  • Kevin A. Harvey

      Affiliations

    • Cellular Biochemistry Laboratory, Methodist Research Institute, Clarian Health, Indianapolis, IN 46202, USA
    • ,
  • Gary P. Zaloga

      Affiliations

    • Clintec Nutrition, One Baxter Parkway, Deerfield, IL 60015, USA

Received 30 April 2007 ,Revised 14 June 2007 ,Accepted 3 July 2007.

References 

  1. Simopoulos AP. Overview of evolutionary aspects of omega 3 fatty acids in the diet. World Rev Nutr Diet. 1998;83:1–11
  2. Bang HO, Dyerberg J, Sinclair HM. The composition of the Eskimo food in north western Greenland. Am J Clin Nutr. 1980;33:2657–2661
  3. Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr. 1975;28:958–966
  4. Berg JP, Glattre E, Haldorsen T, Hostmark AT, Bay IG, Johansen AF, et al. Longchain serum fatty acids and risk of thyroid cancer: a population-based case-control study in Norway. [erratum appears in Cancer Causes Control 1995 Mar; 6(2):182] Cancer Causes Control. 1994;5:433–439
  5. Shekelle R, Missell LV, Paul O, Shyrock AM, Stamler J. Fish consumption and mortality from coronary heart disease. N Engl J Med. 1985;313:820
  6. Norell SE, Ahlbom A, Feychting M, Pedersen NL. Fish consumption and mortality from coronary heart disease. Br Med J Clin Res Ed. 1986;293:426
  7. Schloss I, Kidd MS, Tichelaar HY, Young GO, O'Keefe SJ. Dietary factors associated with a low risk of colon cancer in coloured west coast fishermen. S Afr Med J. 1997;87:152–158
  8. Burdge GC, Jones AE, Wootton SA. Eicosapentaenoic and docosapentaenoic acids are the principal products of alpha-linolenic acid metabolism in young men*. [see comment] Br J Nutr. 2002;88:355–363
  9. Burdge GC, Wootton SA. Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. [see comment] Br J Nutr. 2002;88:411–420
  10. Harper CR, Edwards MJ, DeFilipis AP, Jacobson TA. Flaxseed oil increases the plasma concentrations of cardioprotective (n-3) fatty acids in humans. J Nutr. 2006;136:83–87
  11. Albert C, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA. 1998;279:23–28
  12. Daviglus M, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med. 1997;336:1046–1053
  13. Bang HO, Dyerberg J, Hjoorne N. The composition of food consumed by Greenland Eskimos. Acta Med Scand. 1976;200:69–73
  14. Leaf A, Albert CM, Josephson M, Steinhaus D, Kluger J, Kang JX, et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation. 2005;112:2762–2768
  15. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. [see comment] [erratum appears in Lancet 1995 Mar 18;345(8951):738] Lancet. 1994;343:1454–1459
  16. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. [see comment] [erratum appears in Lancet 2001 Feb 24;357(9256):642] Lancet. 1999;354:447–455
  17. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). [see comments] Lancet. 1989;2:757–761
  18. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. [erratum appears in Circulation. 2006 Jul 4;114(1):e27] Circulation. 2006;114:82–96
  19. Harris WS. n-3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids. 1996;31:243–252
  20. Mori TA, Burke V, Puddey IB, Watts GF, O'Neal DN, Best JD, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr. 2000;71:1085–1094
  21. Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4:385–391
  22. Abe Y, El-Masri B, Kimball KT, Pownall H, Reilly CF, Osmundsen K, et al. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol. 1998;18:723–731
  23. McKenney JM, Sica D. Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. Am J Health Syst Pharm. 2007;64:595–605
  24. Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol. 1996;77:31–36
  25. Thies F, Garry JMC, Yaqoob P, Rerkasem K, Williams J, Shearman CP, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet. 2003;361:477–485
  26. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809
  27. Mori TA, Beilin LJ, Burke V, Morris J, Ritchie J. Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol. 1997;17:279–286
  28. Agren JJ, Vaisanen S, Hanninen O, Muller AD, Hornstra G. Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation. Prostaglandins Leukot Essent Fatty Acids. 1997;57:419–421
  29. Ballantyne CM, Mainolfi EA, Young JB, Windsor NT, Cocanougher B, Lawrence EC, et al. Relationship of increased levels of circulating intercellular adhesion molecule 1 after heart transplantation to rejection: human leukocyte antigen mismatch and survival. J Heart Lung Transplant. 1994;13:597–603
  30. Gearing AJ, Newman W. Circulating adhesion molecules in disease. [see comment] Immunol Today. 1993;14:506–512
  31. De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr. 2000;71:213S–223S
  32. Tagawa H, Shimokawa H, Tagawa T, Kuroiwa-Matsumoto M, Hirooka Y, Takeshita A. Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with coronary artery disease. J Cardiovasc Pharmacol. 1999;33:633–640
  33. Geleijnse JM, Giltay EJ, Grobbee DE, Donders ART, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002;20:1493–1499
  34. Mori TA. Omega-3 fatty acids and hypertension in humans. Clin Exp Pharmacol Physiol. 2006;33:842–846
  35. Locher R, Sachinidis A, Brunner C, Vetter W. Intracellular free calcium concentration and thromboxane A2 formation of vascular smooth muscle cells are influenced by fish oil and n-3 eicosapentaenoic acid. Scand J Clin Lab Invest. 1991;51:541–547
  36. Niggli E. The cardiac sarcoplasmic reticulum: filled with Ca2+ and surprises. [comment] Circ Res. 2007;100:5–6
  37. Berridge MJ. Remodelling Ca2+ signalling systems and cardiac hypertrophy. Biochem Soc Trans. 2006;34:228–231
  38. Berridge MJ. Calcium microdomains: organization and function. Cell Calcium. 2006;40:405–412
  39. Karmazyn M, Horackova M, Murphy MG. Effects of dietary cod liver oil on fatty-acid composition and calcium transport in isolated adult rat ventricular myocytes and on the response of isolated hearts to ischemia and reperfusion. Can J Physiol Pharmacol. 1987;65:201–209
  40. Swanson JE, Lokesh BR, Kinsella JE. Ca2+–Mg2+ ATPase of mouse cardiac sarcoplasmic reticulum is affected by membrane n-6 and n-3 polyunsaturated fatty acid content. J Nutr. 1989;119:364–372
  41. Hallaq H, Sellmayer A, Smith TW, Leaf A. Protective effect of eicosapentaenoic acid on ouabain toxicity in neonatal rat cardiac myocytes. Proc Natl Acad Sci U S A. 1990;87:7834–7838
  42. McLennan PL, Abeywardena MY, Charnock JS. Influence of dietary lipids on arrhythmias and infarction after coronary artery ligation in rats. Can J Physiol Pharmacol. 1985;63:1411–1417
  43. Wallick ET, Dowd F, Allen JC, Schwartz A. The nature of the transport adenosine triphosphatase–digitalis complex. VII. Characteristics of ouabagenin–Na+,K+-adenosine triphosphatase interaction. J Pharmacol Exp Ther. 1974;189:434–444
  44. Hallaq H, Smith TW, Leaf A. Modulation of dihydropyridine-sensitive calcium channels in heart cells by fish oil fatty acids. Proc Natl Acad Sci U S A. 1992;89:1760–1764
  45. Leaf A. Omega-3 fatty acids and prevention of ventricular fibrillation. Prostaglandins Leukot Essent Fatty Acids. 1995;52:197–198
  46. Rinaldi B, Di Pierro P, Vitelli MR, D'Amico M, Berrino L, Rossi F, et al. Effects of docosahexaenoic acid on calcium pathway in adult rat cardiomyocytes. Life Sci. 2002;71:993–1004
  47. Hirafuji M, Ebihara T, Kawahara F, Hamaue N, Endo T, Minami M. Inhibition by docosahexaenoic acid of receptor-mediated Ca(2+) influx in rat vascular smooth muscle cells stimulated with 5-hydroxytryptamine. Eur J Pharmacol. 2001;427:195–201
  48. Hirafuji M, Ebihara T, Kawahara F, Nezu A, Taminura A, Saito H, et al. Effect of docosahexaenoic acid on intracellular calcium dynamics in vascular smooth muscle cells from normotensive and genetically hypertensive rats. Res Commun Mol Pathol Pharmacol. 1998;102:29–42
  49. Xiao YF, Gomez AM, Morgan JP, Lederer WJ, Leaf A. Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci U S A. 1997;94:4182–4187
  50. Honore E, Barhanin J, Attali B, Lesage F, Lazdunski M. External blockade of the major cardiac delayed-rectifier K+ channel (Kv1.5) by polyunsaturated fatty acids. Proc Natl Acad Sci U S A. 1994;91:1937–1941
  51. Kang JX, Xiao YF, Leaf A. Free, long-chain, polyunsaturated fatty acids reduce membrane electrical excitability in neonatal rat cardiac myocytes. Proc Natl Acad Sci U S A. 1995;92:3997–4001
  52. Billman GE, Hallaq H, Leaf A. Prevention of ischemia-induced ventricular fibrillation by omega 3 fatty acids. Proc Natl Acad Sci U S A. 1994;91:4427–4430
  53. Negretti N, Perez MR, Walker D, O'Neill SC. Inhibition of sarcoplasmic reticulum function by polyunsaturated fatty acids in intact, isolated myocytes from rat ventricular muscle. J Physiol. 2000;523(Pt 2):367–375
  54. Pound EM, Kang JX, Leaf A. Partitioning of polyunsaturated fatty acids, which prevent cardiac arrhythmias, into phospholipid cell membranes. J Lipid Res. 2001;42:346–351
  55. Kang JX, Leaf A. Antiarrhythmic effects of polyunsaturated fatty acids. Recent studies. Circulation. 1996;94:1774–1780
  56. Xiao YF, Ke Q, Wang SY, Auktor K, Yang Y, Wang GK, et al. Single point mutations affect fatty acid block of human myocardial sodium channel alpha subunit Na+ channels. Proc Natl Acad Sci U S A. 2001;98:3606–3611
  57. Xiao Y-F, Ma L, Wang S-Y, Josephson ME, Wang GK, Morgan JP, et al. Potent block of inactivation-deficient Na+ channels by n-3 polyunsaturated fatty acids. Am J Physiol— Cell Physiol. 2006;290:C362–C370
  58. Swan JS, Dibb K, Negretti N, O'Neill SC, Sitsapesan R. Effects of eicosapentaenoic acid on cardiac SR Ca(2+)-release and ryanodine receptor function. Cardiovasc Res. 2003;60:337–346
  59. Rvitelli M, Filippelli A, Rinaldi B, Rossi S, Palazzo E, Rossi F, et al. Effects of docosahexaenoic acid on [Ca(2+)](i) increase induced by doxorubicin in ventricular rat cardiomyocytes. Life Sci. 2002;71:1905–1916
  60. Honen BN, Saint DA, Laver DR. Suppression of calcium sparks in rat ventricular myocytes and direct inhibition of sheep cardiac RyR channels by EPA, DHA and oleic acid. J Membr Biol. 2003;196:95–103
  61. Uehara A, Yasukochi M, Imanaga I. Modulation of ryanodine binding to the cardiac Ca2+ release channel by arachidonic acid. J Mol Cell Cardiol. 1996;28:43–51
  62. van Heugten HA, Eskildsen-Helmond YE, de Jonge HW, Bezstarosti K, Lamers JM. Phosphoinositide-generated messengers in cardiac signal transduction. Mol Cell Biochem. 1996;157:5–14
  63. Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem. 2001;70:281–312
  64. Kijima Y, Saito A, Jetton TL, Magnuson MA, Fleischer S. Different intracellular localization of inositol 1,4,5-trisphosphate and ryanodine receptors in cardiomyocytes. J Biol Chem. 1993;268:3499–3506
  65. Hwang K-C, Lim S, Kwon HM, Bae YS, Kang S-M, Chung K-H, et al. Phospholipase C-delta1 rescues intracellular Ca2+ overload in ischemic heart and hypoxic neonatal cardiomyocytes. J Steroid Biochem Mol Biol. 2004;91:131–138
  66. Wing MR, Bourdon DM, Harden TK. PLC-epsilon: a shared effector protein in Ras-, Rho-, and G alpha beta gamma-mediated signaling. Mol Interv. 2003;3:273–280
  67. Sluiter W, Pietersma A, Lamers JM, Koster JF. Leukocyte adhesion molecules on the vascular endothelium: their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression. J Cardiovasc Pharmacol. 1993;22(Suppl 4):S37–S44
  68. Davies PF, Tripathi SC. Mechanical stress mechanisms and the cell. An endothelial paradigm. Circ Res. 1993;72:239–245
  69. Muldowney JAS, Painter CA, Sanders-Bush E, Brown NJ, Vaughan DE. Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of Galphaq, PLC-beta, IP3 and 5,6-epoxyeicosatrienoic acid. Thromb Haemost. 2007;97:263–271
  70. Liu B, Itoh H, Louie O, Kubota K, Kent KC. The role of phospholipase C and phosphatidylinositol 3-kinase in vascular smooth muscle cell migration and proliferation. J Surg Res. 2004;120:256–265
  71. del Valle-Rodriguez A, Lopez-Barneo J, Urena J. Ca2+ channel–sarcoplasmic reticulum coupling: a mechanism of arterial myocyte contraction without Ca2+ influx. EMBO J. 2003;22:4337–4345
  72. Morgan JP, Perreault CL, Morgan KG. The cellular basis of contraction and relaxation in cardiac and vascular smooth muscle. Am Heart J. 1991;121:961–968
  73. Pradhan S, Sumpio B. Molecular and biological effects of hemodynamics on vascular cells. Front Biosci. 2004;9:3276–3285
  74. Asemu G, Dhalla NS, Tappia PS. Inhibition of PLC improves postischemic recovery in isolated rat heart. Am J Physiol Heart Circ Physiol. 2004;287:H2598–H2605
  75. Bian JS, Zhang WM, Xia Q, Wong TM. Phospholipase C inhibitors attenuate arrhythmias induced by kappa-receptor stimulation in the isolated rat heart. J Mol Cell Cardiol. 1998;30:2103–2110
  76. Woodcock EA, Anderson KE, Du XJ, Dart AM. Effects of dietary fat supplementation on inositol phosphate release and metabolism in rat left atria. J Mol Cell Cardiol. 1995;27:867–871
  77. Nair SS, Leitch J, Garg ML. Suppression of inositol phosphate release by cardiac myocytes isolated from fish oil-fed pigs. Mol Cell Biochem. 2000;215:57–64
  78. de Jonge HW, Dekkers DH, Bastiaanse EM, Bezstarosti K, van der Laarse A, Lamers JM. Eicosapentaenoic acid incorporation in membrane phospholipids modulates receptor-mediated phospholipase C and membrane fluidity in rat ventricular myocytes in culture. J Mol Cell Cardiol. 1996;28:1097–1108
  79. Weber C, Erl W, Pietsch A, Danesch U, Weber PC. Docosahexaenoic acid selectively attenuates induction of vascular cell adhesion molecule-1 and subsequent monocytic cell adhesion to human endothelial cells stimulated by tumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol. 1995;15:622–628
  80. Salem N, Shingu T, Kim HY, Hullin F, Bougnoux P, Karanian JW. Specialization in membrane structure and metabolism with respect to polyunsaturated lipids. Prog Clin Biol Res. 1988;282:319–333
  81. Tappia PS, Dent MR, Dhalla NS. Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic Biol Med. 2006;41:349–361
  82. Freyberg Z, Sweeney D, Siddhanta A, Bourgoin S, Frohman M, Shields D. Intracellular localization of phospholipase D1 in mammalian cells. Mol Biol Cell. 2001;12:943–955
  83. Park JB, Kim JH, Kim Y, Ha SH, Yoo JS, Du G, et al. Cardiac phospholipase D2 localizes to sarcolemmal membranes and is inhibited by alpha-actinin in an ADP-ribosylation factor-reversible manner. J Biol Chem. 2000;275:21295–21301
  84. Xu YJ, Panagia V, Shao Q, Wang X, Dhalla NS. Phosphatidic acid increases intracellular free Ca2+ and cardiac contractile force. Am J Physiol. 1996;271:H651–H659
  85. Xu YJ, Botsford MW, Panagia V, Dhalla NS. Responses of heart function and intracellular free Ca2+ to phosphatidic acid in chronic diabetes. Can J Cardiol. 1996;12:1092–1098
  86. Dhalla NS, Xu YJ, Sheu SS, Tappia PS, Panagia V. Phosphatidic acid: a potential signal transducer for cardiac hypertrophy. J Mol Cell Cardiol. 1997;29:2865–2871
  87. Murthy SNP, Chung PH, Lin L, Lomasney JW. Activation of phospholipase Cepsilon by free fatty acids and cross talk with phospholipase D and phospholipase A2. Biochemistry. 2006;45:10987–10997
  88. Becker KP, Hannun YA. Protein kinase C and phospholipase D: intimate interactions in intracellular signaling. Cell Mol Life Sci. 2005;62:1448–1461
  89. Dent MR, Singal T, Dhalla NS, Tappia PS. Expression of phospholipase D isozymes in scar and viable tissue in congestive heart failure due to myocardial infarction. J Cell Mol Med. 2004;8:526–536
  90. Dai J, Williams SA, Ziegelhoffer A, Panagia V. Structure–activity relationship of the effect of cis-unsaturated fatty acids on heart sarcolemmal phospholipase D activity. Prostaglandins Leukot Essent Fatty Acids. 1995;52:167–171
  91. Diaz O, Berquand A, Dubois M, Di Agostino S, Sette C, Bourgoin S, et al. The mechanism of docosahexaenoic acid-induced phospholipase D activation in human lymphocytes involves exclusion of the enzyme from lipid rafts. J Biol Chem. 2002;277:39368–39378[Published online as 10.1074/jbc.M202376200]
  92. Shaikh SR, Siddiqui RA, Lo Cascio D, Stillwell W, Wassall SR. A role for docosahexaenoic acid-containing phosphatidylethanolamine in lipid raft phase separations. Biophys J. 2004;87:1752–1766
  93. Siddiqui RA, Exton JH. Oleate stimulation of diacylglycerol formation from phosphatidylcholine through effects on phospholipase D and phosphatidate phosphohydrolase. Eur J Biochem. 1992;210:601–607
  94. Smani T, Zakharov SI, Csutora P, Leno E, Trepakova ES, Bolotina VM. A novel mechanism for the store-operated calcium influx pathway. Nat Cell Biol. 2004;6:113–120
  95. Oestvang J, Johansen B. Phospholipase A2: a key regulator of inflammatory signalling and a connector to fibrosis development in atherosclerosis. Biochim Biophys Acta. 2006;1761:1309–1316
  96. Reiss AB, Edelman SD. Recent insights into the role of prostanoids in atherosclerotic vascular disease. Curr Vasc Pharmacol. 2006;4:395–408
  97. Giles H. More selective ligands at eicosanoid receptor subtypes improve prospects in inflammatory and cardiovascular research. Trends Pharmacol Sci. 1990;11:301–304
  98. Gerritsen ME. Physiological and pathophysiological roles of eicosanoids in the microcirculation. Cardiovasc Res. 1996;32:720–732
  99. Kudo I, Murakami M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat. 2002;68–69:3–58
  100. Schaloske RH, Dennis EA. The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta. 2006;1761:1246–1259
  101. Touqui L, Alaoui-El-Azher M. Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases. Curr Mol Med. 2001;1:739–754
  102. Schwemmer M, Aho H, Michel JB. Interleukin-1beta-induced type IIA secreted phospholipase A2 gene expression and extracellular activity in rat vascular endothelial cells. Tissue Cell. 2001;33:233–240
  103. Peilot H, Rosengren B, Bondjers G, Hurt-Camejo E. Interferon-gamma induces secretory group IIA phospholipase A2 in human arterial smooth muscle cells. Involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines. J Biol Chem. 2000;275:22895–22904
  104. Pfeilschifter J, Schalkwijk C, Briner VA, van den Bosch H. Cytokine-stimulated secretion of group II phospholipase A2 by rat mesangial cells. Its contribution to arachidonic acid release and prostaglandin synthesis by cultured rat glomerular cells. J Clin Invest. 1993;92:2516–2523
  105. Nakano T, Arita H. Enhanced expression of group II phospholipase A2 gene in the tissues of endotoxin shock rats and its suppression by glucocorticoid. FEBS Lett. 1990;273:23–26
  106. Kuwata H, Nakatani Y, Murakami M, Kudo I. Cytosolic phospholipase A2 is required for cytokine-induced expression of type IIA secretory phospholipase A2 that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3Y1 fibroblasts. J Biol Chem. 1998;273:1733–1740
  107. Murakami M, Nakatani Y, Atsumi G, Inoue K, Kudo I. Regulatory functions of phospholipase A2. Crit Rev Immunol. 1997;17:225–283
  108. Webb NR. Secretory phospholipase A2 enzymes in atherogenesis. Curr Opin Lipidol. 2005;16:341–344
  109. Murakami M, Kudo I. New phospholipase A(2) isozymes with a potential role in atherosclerosis. Curr Opin Lipidol. 2003;14:431–436
  110. Qiu ZH, Gijon MA, de Carvalho MS, Spencer DM, Leslie CC. The role of calcium and phosphorylation of cytosolic phospholipase A2 in regulating arachidonic acid release in macrophages. J Biol Chem. 1998;273:8203–8211
  111. de Carvalho MG, McCormack AL, Olson E, Ghomashchi F, Gelb MH, Yates JR, et al. Identification of phosphorylation sites of human 85-kDa cytosolic phospholipase A2 expressed in insect cells and present in human monocytes. J Biol Chem. 1996;271:6987–6997
  112. Diez E, Louis-Flamberg P, Hall RH, Mayer RJ. Substrate specificities and properties of human phospholipases A2 in a mixed vesicle model. J Biol Chem. 1992;267:18342–18348
  113. Hanel AM, Schuttel S, Gelb MH. Processive interfacial catalysis by mammalian 85-kilodalton phospholipase A2 enzymes on product-containing vesicles: application to the determination of substrate preferences. Biochemistry. 1993;32:5949–5958
  114. Clark JD, Lin LL, Kriz RW, Ramesha CS, Sultzman LA, Lin AY, et al. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell. 1991;65:1043–1051
  115. Tang J, Kriz RW, Wolfman N, Shaffer M, Seehra J, Jones SS. A novel cytosolic calcium-independent phospholipase A2 contains eight ankyrin motifs. J Biol Chem. 1997;272:8567–8575
  116. Pavoine C, Defer N. The cardiac beta2-adrenergic signalling a new role for the cPLA2. Cell Signal. 2005;17:141–152
  117. Grynberg A, Nalbone G, Leonardi J, Lafont H, Athias P. Eicosapentaenoic and docosahexaenoic acids in cultured rat ventricular myocytes and hypoxia-induced alterations of phospholipase-A activity. Mol Cell Biochem. 1992;116:75–78
  118. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271:33157–33160
  119. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res. 2000;41:163–181
  120. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. [see comment] FASEB J. 1998;12:1063–1073
  121. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983;220:568–575
  122. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294:1871–1875
  123. Spiecker M, Liao JK. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys. 2005;433:413–420
  124. Elbekai RH, El-Kadi AOS. Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther. 2006;112:564–587
  125. Osher E, Weisinger G, Limor R, Tordjman K, Stern N. The 5 lipoxygenase system in the vasculature: emerging role in health and disease. Mol Cell Endocrinol. 2006;252:201–206
  126. Chandrasekharan NV, Dai H, Roos KLT, Evanson NK, Tomsik J, Elton TS, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. [see comment] Proc Natl Acad Sci U S A. 2002;99:13926–13931
  127. Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A. 2001;98:3358–3363
  128. Pakala R, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation. 1997;96:2280–2286
  129. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation. 2001;104:921–927
  130. Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol. 1999;19:646–655
  131. von Schacky C, Kiefl R, Marcus AJ, Broekman MJ, Kaminski WE. Dietary n-3 fatty acids accelerate catabolism of leukotriene B4 in human granulocytes. Biochim Biophys Acta. 1993;1166:20–24
  132. Laneuville O, Breuer DK, Xu N, Huang ZH, Gage DA, Watson JT, et al. Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)-octadecatrienoic acids from alpha-linolenic acid. J Biol Chem. 1995;270:19330–19336
  133. Hwang D. Fatty acids and immune responses — a new perspective in searching for clues to mechanism. Annu Rev Nutr. 2000;20:431–456
  134. Sellmayer A, Hrboticky N, Weber PC. Lipids in vascular function. Lipids. 1999;34(Suppl):S13–S18
  135. Corey EJ, Shih C, Cashman JR. Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc Natl Acad Sci U S A. 1983;80:3581–3584
  136. Smith WL. Omega-3 and omega-6 essential fatty acids and cyclooxygenase pathways. FASEB J. 2006;20:576;[abstract]
  137. Ringbom T, Huss U, Stenholm A, Flock S, Skattebol L, Perera P, et al. Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001;64:745–749
  138. Spector AA, Kaduce TL, Figard PH, Norton KC, Hoak JC, Czervionke RL. Eicosapentaenoic acid and prostacyclin production by cultured human endothelial cells. J Lipid Res. 1983;24:1595–1604
  139. Ait-Said F, Elalamy I, Werts C, Gomard MT, Jacquemin C, Couetil J-P, et al. Inhibition by eicosapentaenoic acid of IL-1beta-induced PGHS-2 expression in human microvascular endothelial cells: involvement of lipoxygenase-derived metabolites and p38 MAPK pathway. Biochim Biophys Acta. 2003;1631:77–84
  140. Lee JY, Plakidas A, Lee WH, Heikkinen A, Chanmugam P, Bray G, et al. Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003;44:479–486
  141. Machida T, Hiramatsu M, Hamaue N, Minami M, Hirafuji M. Docosahexaenoic acid enhances cyclooxygenase-2 induction by facilitating p44/42, but not p38, mitogen-activated protein kinase activation in rat vascular smooth muscle cells. J Pharmacol Sci. 2005;99:113–116
  142. Gilbert M, Dalloz S, Maclouf J, Lagarde M. Differential effects of long chain n-3 fatty acids on the expression of PGH synthase isoforms in bovine aortic endothelial cells. Prostaglandins Leukot Essent Fatty Acids. 1999;60:363–365
  143. Culp BR, Titus BG, Lands WE. Inhibition of prostaglandin biosynthesis by eicosapentaenoic acid. Prostaglandins Med. 1979;3:269–278
  144. Fischer S, von Schacky C, Siess W, Strasser T, Weber PC. Uptake, release and metabolism of docosahexaenoic acid (DHA, c22:6 omega 3) in human platelets and neutrophils. Biochem Biophys Res Commun. 1984;120:907–918
  145. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990;323:645–655
  146. De Caterina R, Zampolli A. From asthma to atherosclerosis-5-lipoxygenase, leukotrienes, and inflammation. [comment] N Engl J Med. 2004;350:4–7
  147. Back M, Hansson GK. Leukotriene receptors in atherosclerosis. Ann Med. 2006;38:493–502
  148. Smith MJ, Ford-Hutchinson AW, Bray MA. Leukotriene B: a potential mediator of inflammation. J Pharm Pharmacol. 1980;32:517–518
  149. Joris I, Majno G, Corey EJ, Lewis RA. The mechanism of vascular leakage induced by leukotriene E4. Endothelial contraction. Am J Pathol. 1987;126:19–24
  150. Hedqvist P, Dahlen SE, Gustafsson L, Hammarstrom S, Samuelsson B. Biological profile of leukotrienes C4 and D4. Acta Physiol Scand. 1980;110:331–333
  151. Soter NA, Lewis RA, Corey EJ, Austen KF. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol. 1983;80:115–119
  152. Dahlen SE, Bjork J, Hedqvist P, Arfors KE, Hammarstrom S, Lindgren JA, et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci U S A. 1981;78:3887–3891
  153. Brink C, Dahlen S-E, Drazen J, Evans JF, Hay DWP, Nicosia S, et al. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev. 2003;55:195–227
  154. Strasser T, Fischer S, Weber PC. Leukotriene B5 is formed in human neutrophils after dietary supplementation with eicosapentaenoic acid. Proc Natl Acad Sci U S A. 1985;82:1540–1543
  155. Prescott SM. The effect of eicosapentaenoic acid on leukotriene B production by human neutrophils. J Biol Chem. 1984;259:7615–7621
  156. Lee TH, Menica-Huerta JM, Shih C, Corey EJ, Lewis RA, Austen KF. Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product. J Biol Chem. 1984;259:2383–2389
  157. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A. 2003;100:1238–1243
  158. Cipollone F, Mezzetti A, Fazia ML, Cuccurullo C, Iezzi A, Ucchino S, et al. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol. 2005;25:1665–1670
  159. Back M. Functional characteristics of cysteinyl-leukotriene receptor subtypes. Life Sci. 2002;71:611–622
  160. Back M, Bu D-x, Branstrom R, Sheikine Y, Yan Z-Q, Hansson GK. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A. 2005;102:17501–17506
  161. Lotzer K, Spanbroek R, Hildner M, Urbach A, Heller R, Bretschneider E, et al. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arterioscler Thromb Vasc Biol. 2003;23:e32–e36
  162. Allen SP, Dashwood MR, Chester AH, Tadjkarimi S, Collins M, Piper PJ, et al. Influence of atherosclerosis on the vascular reactivity of isolated human epicardial coronary arteries to leukotriene C4. Cardioscience. 1993;4:47–54
  163. Qiu H, Gabrielsen A, Agardh HE, Wan M, Wetterholm A, Wong C-H, et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci U S A. 2006;103:8161–8166
  164. Ortiz JL, Gorenne I, Cortijo J, Seller A, Labat C, Sarria B, et al. Leukotriene receptors on human pulmonary vascular endothelium. Br J Pharmacol. 1995;115:1382–1386
  165. Back M, Norel X, Walch L, Gascard J, de Montpreville V, Dahlen S, et al. Prostacyclin modulation of contractions of the human pulmonary artery by cysteinyl-leukotrienes. Eur J Pharmacol. 2000;401:389–395
  166. Back M, Walch L, Norel X, Gascard JP, Mazmanian G, Brink C. Modulation of vascular tone and reactivity by nitric oxide in porcine pulmonary arteries and veins. Acta Physiol Scand. 2002;174:9–15
  167. Uzonyi B, Lotzer K, Jahn S, Kramer C, Hildner M, Bretschneider E, et al. Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells. Proc Natl Acad Sci U S A. 2006;103:6326–6331
  168. Kamohara M, Takasaki J, Matsumoto M, Matsumoto S, Saito T, Soga T, et al. Functional characterization of cysteinyl leukotriene CysLT(2) receptor on human coronary artery smooth muscle cells. Biochem Biophys Res Commun. 2001;287:1088–1092
  169. Grandel U, Benkelmann R, Buerke M, Kiss L, Hattar K, Mayer K, et al. Free arachidonic versus eicosapentaenoic acid differentially influences the potency of bacterial exotoxins to provoke myocardial depression in isolated rat hearts. Crit Care Med. 2006;34:118–126
  170. Grimminger F, Wahn H, Mayer K, Kiss L, Walmrath D, Seeger W. Impact of arachidonic versus eicosapentaenoic acid on exotonin-induced lung vascular leakage: relation to 4-series versus 5-series leukotriene generation. Am J Respir Crit Care Med. 1997;155:513–519
  171. Seya A, Terano T, Tamura Y, Yoshida S. Comparative effect of leukotriene B4 and leukotriene B5 on calcium mobilization in human neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1988;34:47–50
  172. Grimminger F, Grimm H, Fuhrer D, Papavassilis C, Lindemann G, Blecher C, et al. Omega-3 lipid infusion in a heart allotransplant model. Shift in fatty acid and lipid mediator profiles and prolongation of transplant survival. Circulation. 1996;93:365–371
  173. Serhan CN. Novel chemical mediators in the resolution of inflammation: resolvins and protectins. Anesthesiol Clin. 2006;24:341–364
  174. Arita M, Clish CB, Serhan CN. The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids. Biochem Biophys Res Commun. 2005;338:149–157
  175. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 2000;192:1197–1204
  176. Wang MH, Guan H, Nguyen X, Zand BA, Nasjletti A, Laniado-Schwartzman M. Contribution of cytochrome P-450 4A1 and 4A2 to vascular 20-hydroxyeicosatetraenoic acid synthesis in rat kidneys. Am J Physiol. 1999;276:F246–F253
  177. Zhang Y, Oltman CL, Lu T, Lee HC, Dellsperger KC, VanRollins M. EET homologs potently dilate coronary microvessels and activate BK(Ca) channels. Am J Physiol Heart Circ Physiol. 2001;280:H2430–H2440
  178. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82:131–185
  179. Gebremedhin D, Ma YH, Falck JR, Roman RJ, VanRollins M, Harder DR. Mechanism of action of cerebral epoxyeicosatrienoic acids on cerebral arterial smooth muscle. Am J Physiol. 1992;263:H519–H525
  180. Ye D, Zhang D, Oltman C, Dellsperger K, Lee H-C, VanRollins M. Cytochrome p-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels. J Pharmacol Exp Ther. 2002;303:768–776
  181. Harmon SD, Fang X, Kaduce TL, Hu S, Raj Gopal V, Falck JR, et al. Oxygenation of omega-3 fatty acids by human cytochrome P450 4F3B: effect on 20-hydroxyeicosatetraenoic acid production. Prostaglandins Leukot Essent Fatty Acids. 2006;75:169–177
  182. Dubois M, Croset M, Nemoz G, Lagarde M, Prigent AF. Modulation of cyclic nucleotide phosphodiesterase by dietary fats in rat heart. Lipids. 1992;27:746–754
  183. Wince LC, Rutledge CO. The effect of dietary lipid on the binding of [3H] dihydroalprenolol and adenylate cyclase activity in rat atria. J Pharmacol Exp Ther. 1981;219:625–631
  184. MacLeod DC, Heagerty AM, Bund SJ, Lawal TS, Riemersma RA. Effect of dietary polyunsaturated fatty acids on contraction and relaxation of rat femoral resistance arteries. J Cardiovasc Pharmacol. 1994;23:92–98
  185. Skuladottir GV, Schioth HB, Gudbjarnason S. Polyunsaturated fatty acids in heart muscle and alpha 1-adrenoceptor binding properties. Biochim Biophys Acta. 1993;1178:49–54
  186. Yin K, Chu ZM, Beilin LJ. Blood pressure and vascular reactivity changes in spontaneously hypertensive rats fed fish oil. Br J Pharmacol. 1991;102:991–997
  187. Brodde O-E, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci. 2006;100:323–337
  188. Grynberg A, Fournier A, Sergiel JP, Athias P. Effect of docosahexaenoic acid and eicosapentaenoic acid in the phospholipids of rat heart muscle cells on adrenoceptor responsiveness and mechanism. J Mol Cell Cardiol. 1995;27:2507–2520
  189. Grynberg A, Fournier A, Sergiel JP, Athias P. Membrane docosahexaenoic acid vs. eicosapentaenoic acid and the beating function of the cardiomyocyte and its regulation through the adrenergic receptors. Lipids. 1996;31(Suppl):S205–S210
  190. Kang JX, Leaf A. Evidence that free polyunsaturated fatty acids modify Na+ channels by directly binding to the channel proteins. Proc Natl Acad Sci U S A. 1996;93:3542–3546
  191. Price SA, Tisdale MJ. Mechanism of inhibition of a tumor lipid-mobilizing factor by eicosapentaenoic acid. Cancer Res. 1998;58:4827–4831
  192. Courtois M, Khatami S, Fantini E, Athias P, Mielle P, Grynberg A. Polyunsaturated fatty acids in cultured cardiomyocytes: effect on physiology and beta-adrenoceptor function. Am J Physiol. 1992;262:H451–H456
  193. Yan C, Miller CL, Abe J. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res. 2007;100:489–501
  194. Picq M, Dubois M, Grynberg A, Lagarde M, Prigent AF. Specific effects of n-3 fatty acids and 8-bromo-cGMP on the cyclic nucleotide phosphodiesterase activity in neonatal rat cardiac myocytes. J Mol Cell Cardiol. 1996;28:2151–2161
  195. Dubois M, Picq M, Nemoz G, Lagarde M, Prigent AF. Inhibition of the different phosphodiesterase isoforms of rat heart cytosol by free fatty acids. J Cardiovasc Pharmacol. 1993;21:522–529
  196. Hartzell HC, Fischmeister R. Opposite effects of cyclic GMP and cyclic AMP on Ca2+ current in single heart cells. Nature. 1986;323:273–275
  197. Kuriyama H, Kitamura K, Nabata H. Pharmacological and physiological significance of ion channels and factors that modulate them in vascular tissues. Pharmacol Rev. 1995;47:387–573
  198. Levitan IB. Modulation of ion channels by protein phosphorylation and dephosphorylation. Annu Rev Physiol. 1994;56:193–212
  199. McDonald TF, Pelzer S, Trautwein W, Pelzer DJ. Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol Rev. 1994;74:365–507
  200. Hatakeyama N, Mukhopadhyay D, Goyal RK, Akbarali HI. Tyrosine kinase-dependent modulation of calcium entry in rabbit colonic muscularis mucosae. Am J Physiol. 1996;270:C1780–C1789
  201. Di Salvo J, Steusloff A, Semenchuk L, Satoh S, Kolquist K, Pfitzer G. Tyrosine kinase inhibitors suppress agonist-induced contraction in smooth muscle. Biochem Biophys Res Commun. 1993;190:968–974
  202. Hu XQ, Singh N, Mukhopadhyay D, Akbarali HI. Modulation of voltage-dependent Ca2+ channels in rabbit colonic smooth muscle cells by c-Src and focal adhesion kinase. J Biol Chem. 1998;273:5337–5342
  203. Chen W, Jump DB, Esselman WJ, Busik JV. Inhibition of cytokine signaling in human retinal endothelial cells through modification of caveolae/lipid rafts by docosahexaenoic acid. Invest Ophthalmol Vis Sci. 2007;48:18–26
  204. Ishida M, Marrero MB, Schieffer B, Ishida T, Bernstein KE, Berk BC. Angiotensin II activates pp60c-src in vascular smooth muscle cells. Circ Res. 1995;77:1053–1059
  205. Kypta RM, Goldberg Y, Ulug ET, Courtneidge SA. Association between the PDGF receptor and members of the src family of tyrosine kinases. Cell. 1990;62:481–492
  206. Parsons JT, Parsons SJ. Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Curr Opin Cell Biol. 1997;9:187–192
  207. Thorburn A, Thorburn J, Chen SY, Powers S, Shubeita HE, Feramisco JR, et al. HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy. [published erratum appears in J Biol Chem 1993 Jul 25;268(21):16082] J Biol Chem. 1993;268:2244–2249
  208. Gottshall KR, Hunter JJ, Tanaka N, Dalton N, Becker KD, Ross J, et al. Ras-dependent pathways induce obstructive hypertrophy in echo-selected transgenic mice. Proc Natl Acad Sci U S A. 1997;94:4710–4715
  209. Hunter JJ, Tanaka N, Rockman HA, Ross J, Chien KR. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem. 1995;270:23173–23178
  210. Siddiqui RA, Shaikh SR, Kovacs R, Stillwell W, Zaloga G. Inhibition of phenylephrine-induced cardiac hypertrophy by docosahexaenoic acid. J Cell Biochem. 2004;92:1141–1159
  211. Ho PD, Zechner DK, He H, Dillmann WH, Glembotski CC, McDonough PM. The Raf-MEK-ERK cascade represents a common pathway for alteration of intracellular calcium by Ras and protein kinase C in cardiac myocytes. J Biol Chem. 1998;273:21730–21735
  212. Komuro I, Katoh Y, Kaida T, Shibazaki Y, Kurabayashi M, Hoh E, et al. Mechanical loading stimulates cell hypertrophy and specific gene expression in cultured rat cardiac myocytes. Possible role of protein kinase C activation. J Biol Chem. 1991;266:1265–1268
  213. Komuro I, Kaida T, Shibazaki Y, Kurabayashi M, Katoh Y, Hoh E, et al. Stretching cardiac myocytes stimulates protooncogene expression. J Biol Chem. 1990;265:3595–3598
  214. Thorburn J, Frost JA, Thorburn A. Mitogen-activated protein kinases mediate changes in gene expression, but not cytoskeletal organization associated with cardiac muscle cell hypertrophy. J Cell Biol. 1994;126:1565–1572
  215. Seko Y, Tobe K, Ueki K, Kadowaki T, Yazaki Y. Hypoxia and hypoxia/reoxygenation activate Raf-1, mitogen-activated protein kinase kinase, mitogen-activated protein kinases, and S6 kinase in cultured rat cardiac myocytes. Circ Res. 1996;78:82–90
  216. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J. 1995;9:726–735
  217. Yamazaki T, Tobe K, Hoh E, Maemura K, Kaida T, Komuro I, et al. Mechanical loading activates mitogen-activated protein kinase and S6 peptide kinase in cultured rat cardiac myocytes. J Biol Chem. 1993;268:12069–12076
  218. Terano T, Shiina T, Saito J, Tamura Y, Yoshida S. Eicosapentaenoic acid suppressed the proliferation of vascular smooth muscle cells through modulation of binding of growth factor. Jpn J Pharmacol. 1992;58(Suppl 2):286
  219. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell. 1986;46:155–169
  220. Mizutani M, Asano M, Roy S, Nakajima T, Soma M, Yamashita K, et al. Omega-3 polyunsaturated fatty acids inhibit migration of human vascular smooth muscle cells in vitro. Life Sci. 1997;61:PL269–PL274
  221. Morrison DK, Cutler RE. The complexity of Raf-1 regulation. Curr Opin Cell Biol. 1997;9:174–179
  222. Ghosh S, Bell RM. Regulation of Raf-1 kinase by interaction with the lipid second messenger, phosphatidic acid. Biochem Soc Trans. 1997;25:561–565
  223. Sah VP, Hoshijima M, Chien KR, Brown JH. Rho is required for Galphaq and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. J Biol Chem. 1996;271:31185–31190
  224. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997;11:2295–2322
  225. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 1996;15:2208–2216
  226. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem. 1995;270:29051–29054
  227. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). [see comment] Science. 1996;273:245–248
  228. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem. 1996;271:20246–20249
  229. Hirata K, Kikuchi A, Sasaki T, Kuroda S, Kaibuchi K, Matsuura Y, et al. Involvement of rho p21 in the GTP-enhanced calcium ion sensitivity of smooth muscle contraction. J Biol Chem. 1992;267:8719–8722
  230. Kureishi Y, Kobayashi S, Amano M, Kimura K, Kanaide H, Nakano T, et al. Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem. 1997;272:12257–12260
  231. Adamson P, Marshall CJ, Hall A, Tilbrook PA. Post-translational modifications of p21rho proteins. J Biol Chem. 1992;267:20033–20038
  232. Murphy S, Frishman WH. Protein kinase C in cardiac disease and as a potential therapeutic target. Cardiol Rev. 2005;13:3–12
  233. Dorn GW, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest. 2005;115:527–537
  234. Naruse K, King GL. Protein kinase C and myocardial biology and function. Circ Res. 2000;86:1104–1106
  235. Lynch JJ, Ferro TJ, Blumenstock FA, Brockenauer AM, Malik AB. Increased endothelial albumin permeability mediated by protein kinase C activation. J Clin Invest. 1990;85:1991–1998
  236. Cagliero E, Roth T, Roy S, Maiello M, Lorenzi M. Expression of genes related to the extracellular matrix in human endothelial cells. Differential modulation by elevated glucose concentrations, phorbol esters, and cAMP. J Biol Chem. 1991;266:14244–14250
  237. Smirnov VN, Antonov AS, Antonova GN, Romanov YA, Kabaeva NV, Tchertikhina IV, et al. Effects of forskolin and phorbol-myristate-acetate on cytoskeleton, extracellular matrix and protein phosphorylation in human endothelial cells. J Mol Cell Cardiol. 1989;21(Suppl 1):3–11
  238. Naito S, Shimizu S, Matsuu M, Nakashima M, Nakayama T, Yamashita S, et al. Ets-1 upregulates matrix metalloproteinase-1 expression through extracellular matrix adhesion in vascular endothelial cells. Biochem Biophys Res Commun. 2002;291:130–138
  239. Okada M, Matsumori A, Ono K, Furukawa Y, Shioi T, Iwasaki A, et al. Cyclic stretch upregulates production of interleukin-8 and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in human endothelial cells. Arterioscler Thromb Vasc Biol. 1998;18:894–901
  240. Kondo A, Isaji S, Nishimura Y, Tanaka T. Transcriptional and post-transcriptional regulation of monocyte chemoattractant protein-3 gene expression in human endothelial cells by phorbol ester and cAMP signalling. Immunology. 2000;99:561–568
  241. Aviv A. Cytosolic Ca2+, Na+/H+ antiport, protein kinase C trio in essential hypertension. Am J Hypertens. 1994;7:205–212
  242. Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI, Buttrick PM. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest. 1997;100:2189–2195
  243. Strasser RH, Simonis G, Schon SP, Braun MU, Ihl-Vahl R, Weinbrenner C, et al. Two distinct mechanisms mediate a differential regulation of protein kinase C isozymes in acute and prolonged myocardial ischemia. Circ Res. 1999;85:77–87
  244. Mochly-Rosen D, Wu G, Hahn H, Osinska H, Liron T, Lorenz JN, et al. Cardiotrophic effects of protein kinase C epsilon: analysis by in vivo modulation of PKCepsilon translocation. [see comment] Circ Res. 2000;86:1173–1179
  245. Jalili T, Takeishi Y, Walsh RA. Signal transduction during cardiac hypertrophy: the role of G alpha q, PLC beta I, and PKC. Cardiovasc Res. 1999;44:5–9
  246. Sabri A, Steinberg SF. Protein kinase C isoform-selective signals that lead to cardiac hypertrophy and the progression of heart failure. Mol Cell Biochem. 2003;251:97–101
  247. Steinberg SF, Goldberg M, Rybin VO. Protein kinase C isoform diversity in the heart. J Mol Cell Cardiol. 1995;27:141–153
  248. Mochly-Rosen D. Localization of protein kinases by anchoring proteins: a theme in signal transduction. Science. 1995;268:247–251
  249. Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J. 1998;332:281–292
  250. Laser M, Kasi VS, Hamawaki M, Cooper G, Kerr CM, Kuppuswamy D. Differential activation of p70 and p85 S6 kinase isoforms during cardiac hypertrophy in the adult mammal. J Biol Chem. 1998;273:24610–24619
  251. Nyby MD, Hori MT, Ormsby B, Gabrielian A, Tuck ML. Eicosapentaenoic acid inhibits Ca2+ mobilization and PKC activity in vascular smooth muscle cells. Am J Hypertens. 2003;16:708–714
  252. Castillo A, Ruzmetov N, Harvey K, Stillwell W, Zaloga GP, Siddiqui R. Docosahexaenoic acid inhibits protein kinase C translocation/activation and cardiac hypertrophy in rat cardiomyocytes. J Mol Genet Med. 2005;1:18–25
  253. Graber R, Sumida C, Nunez EA. Fatty acids and cell signal transduction. J Lipid Mediators Cell Signal. 1994;9:91–116
  254. Bordoni A, Biagi PL, Turchetto E, Rossi CA, Hrelia S. Diacylglycerol fatty acid composition is related to activation of protein kinase C in cultured cardiomyocytes. Cardioscience. 1992;3:251–255
  255. Takahashi R, Okumura K, Asai T, Hirai T, Murakami H, Murakami R, et al. Dietary fish oil attenuates cardiac hypertrophy in lipotoxic cardiomyopathy due to systemic carnitine deficiency. [see comment] Cardiovasc Res. 2005;68:213–223
  256. Terano T, Shiina T, Tamura Y. Eicosapentaenoic acid suppressed the proliferation of vascular smooth muscle cells through modulation of various steps of growth signals. Lipids. 1996;31(Suppl):S301–S304
  257. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 1992;258:607–614
  258. McPhail LC, Clayton CC, Snyderman R. A potential second messenger role for unsaturated fatty acids: activation of Ca2+-dependent protein kinase. Science. 1984;224:622–625
  259. Goldberg EM, Zidovetzki R. Effects of dipalmitoylglycerol and fatty acids on membrane structure and protein kinase C activity. Biophys J. 1997;73:2603–2614
  260. De Jonge HW, Van Heugten HA, Lamers JM. Signal transduction by the phosphatidylinositol cycle in myocardium. J Mol Cell Cardiol. 1995;27:93–106
  261. Holian O, Nelson R. Action of long-chain fatty acids on protein kinase C activity: comparison of omega-6 and omega-3 fatty acids. Anticancer Res. 1992;12:975–980
  262. Philibert A, Vanier C, Abdelouahab N, Chan HM, Mergler D. Fish intake and serum fatty acid profiles from freshwater fish. Am J Clin Nutr. 2006;84:1299–1307
  263. Kuriki K, Nagaya T, Imaeda N, Tokudome Y, Fujiwara N, Sato J, et al. Discrepancies in dietary intakes and plasma concentrations of fatty acids according to age among Japanese female dietitians. Eur J Clin Nutr. 2002;56:524–531
  264. Minami M, Kimura S, Endo T, Hamaue N, Hirafuji M, Togashi H, et al. Dietary docosahexaenoic acid increases cerebral acetylcholine levels and improves passive avoidance performance in stroke-prone spontaneously hypertensive rats. Pharmacol Biochem Behav. 1997;58:1123–1129

PII: S0955-2863(07)00165-9

doi: 10.1016/j.jnutbio.2007.07.001

The Journal of Nutritional Biochemistry
Volume 19, Issue 7 , Pages 417-437 , July 2008

Article Tools

* Image Usage & Resolution